Campbell Ellsworth M, Chao Lin
Section of Ecology, Behavior and Evolution, Division of Biological Sciences, University of California San Diego, La Jolla, California, United States of America.
PLoS One. 2014 Jan 31;9(1):e86971. doi: 10.1371/journal.pone.0086971. eCollection 2014.
The evolution of antibiotic resistance in microbes poses one of the greatest challenges to the management of human health. Because addressing the problem experimentally has been difficult, research on strategies to slow the evolution of resistance through the rational use of antibiotics has resorted to mathematical and computational models. However, despite many advances, several questions remain unsettled. Here we present a population model for rational antibiotic usage by adding three key features that have been overlooked: 1) the maximization of the frequency of uninfected patients in the human population rather than the minimization of antibiotic resistance in the bacterial population, 2) the use of cocktails containing antibiotic pairs, and 3) the imposition of tradeoff constraints on bacterial resistance to multiple drugs. Because of tradeoffs, bacterial resistance does not evolve directionally and the system reaches an equilibrium state. When considering the equilibrium frequency of uninfected patients, both cycling and mixing improve upon single-drug treatment strategies. Mixing outperforms optimal cycling regimens. Cocktails further improve upon aforementioned strategies. Moreover, conditions that increase the population frequency of uninfected patients also increase the recovery rate of infected individual patients. Thus, a rational strategy does not necessarily result in a tragedy of the commons because benefits to the individual patient and general public are not in conflict. Our identification of cocktails as the best strategy when tradeoffs between multiple-resistance are operating could also be extended to other host-pathogen systems. Cocktails or other multiple-drug treatments are additionally attractive because they allow re-using antibiotics whose utility has been negated by the evolution of single resistance.
微生物对抗生素耐药性的演变是人类健康管理面临的最大挑战之一。由于通过实验解决这一问题困难重重,关于通过合理使用抗生素来减缓耐药性演变策略的研究诉诸于数学和计算模型。然而,尽管取得了许多进展,但仍有几个问题尚未解决。在此,我们通过添加三个被忽视的关键特征,提出了一个合理使用抗生素的种群模型:1)使人群中未感染患者的频率最大化,而非使细菌种群中的抗生素耐药性最小化;2)使用包含抗生素对的联合用药;3)对细菌对多种药物的耐药性施加权衡约束。由于存在权衡,细菌耐药性不会定向进化,系统会达到平衡状态。在考虑未感染患者的平衡频率时,循环用药和联合用药都优于单一药物治疗策略。联合用药优于最优循环用药方案。联合用药进一步改进了上述策略。此外,增加未感染患者种群频率的条件也会提高感染个体患者的康复率。因此,合理的策略不一定会导致公地悲剧,因为对个体患者和公众的益处并不冲突。我们确定在多重耐药性存在权衡时联合用药是最佳策略,这一点也可推广到其他宿主 - 病原体系统。联合用药或其他多种药物治疗还具有吸引力,因为它们允许重新使用因单一耐药性演变而效用丧失的抗生素。